Letter

Shared scheme for assessing drugs for multiple sclerosis: Why are eyes tightly shut to considering causes other than autoimmunity?

BMJ 2003; 326 doi: 10.1136/bmj.326.7400.1213 (Published 29 May 2003)
Cite this as: BMJ 2003;326:1213.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Abhijit Chaudhuri, senior lecturer in clinical neurosciences (ac54p@udcf.gla.ac.uk),
  2. Peter O Behan, emeritus professor of neurology
  1. University of Glasgow Department of Neurology, Institute of Neurological Sciences, South Glasgow University Hospitals NHS Trust, Glasgow G51 4TF

    EDITOR—We agree with Sudlow and Counsell that the evidence for the risk sharing scheme for interferon beta and glatiramer in multiple sclerosis is poor.1 There are serious clinical and scientific flaws in advocating immunological treatments for multiple sclerosis.2 Before committing precious resources to any trial involving several thousand patients as proposed1 we have to …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular